Open-to-Accrual Therapeutic Trials


Thoracic Oncology (Lung)

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

NRG-LU002 ClinicalTrials.gov:  NCT03137771

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial S. Ghamande Kelly Adams Non-Small Cell Lung Cancer II/III

A081105 (ALCHEMIST)  ClinicalTrials.gov:   NCT02193282

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) S. Ghamande Inquiries Small Cell Lung Cancer III

E4512 (ALCHEMIST)  ClinicalTrials,gov:   NCT02201992

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein S. Ghamande Inquiries Small Cell Lung Cancer III

EA5142  ClinicalTrials.gov:   NCT02595944

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer S. Ghamande Inquiries Small Cell Lung Cancer III